ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Closed-Loop-Capable Neural Interface Platform for Deep Brain Modulation via Integrated Non-Viral Gene Delivery, NIR Optogenetics, and Electrophysiological Recording.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Closed-Loop-Capable Neural Interface Platform for Deep Brain Modulation via Integrated Non-Viral Gene Delivery, NIR Optogenetics, and Electrophysiological Recording.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Closed-loop neuromodulation requires precise, stable, and cell-specific control of neural circuits with minimal invasiveness. However, conventional optogenetic systems are hindered by invasive optical fibers, viral-based gene delivery, and disjointed hardware modules. Here, a multifunctional neural interface integrating non-viral delivery of AAV-derived Channelrhodopsin-2 (ChR2) gene plasmid, fiberless intracranial optogenetic stimulation via externally delivered near-infrared (NIR) excitation, and electrophysiological recording into a single implantable device is reported. The core of this interface is a 3D gold inverse opal (AuIO) microelectrode that provides high surface area, promoting both electroporation-mediated gene transfection and neural signal acquisition. ChR2-expressing plasmid DNA is complexed with polyethyleneimine-neurotensin (NT-PEI) as non-viral gene vectors that are immobilized onto designated electrode sites for neuron-targeted localized gene expression. Upconversion nanoparticles (UCNPs) embedded in a gelatin methacryloyl (GelMA) matrix are precisely integrated onto the microscale AuIO surface via aerosol jet printing, enabling localized surface plasmon resonance (LSPR)-enhanced NIR-to-blue light conversion for remote optogenetic activation. In vivo implantation into the hippocampal dentate gyrus (DG) demonstrates successful opsin expression and real-time light-evoked neural activity via single surgical step. This all-in-one platform provides a fiber-free, biocompatible neural interface capable of stable in vivo operation for deep-brain optogenetic engineering, paving the way for precision closed-loop neuromodulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.